Four drugs have been tried out on patients in the Democratic Republic of Congo where there has been a major outbreak of the virus.
Research shows that if caught early enough there is a 90% survival rate using the drugs.
The plan now by health officials is to use the medication to treat all Ebola patients in DR Congo.
More than 1,800 people have died in DR Congo in the last year.
It is a big forward step in treating the virus that has wiped out thousands of people.
The latest outbreak in DR Congo began a year ago with the World Health Organisation saying the Ebola crisis is a “public health emergency of international concern”.
In the biggest ever epidemic, 11,310 people died in Western Africa, with 28,616 infected.
Jeremy Farrar, Wellcome Trust director, said the new treatment would “undoubtedly save lives”.
He added that scientists are getting close to turning Ebola into a “preventable and treatable” disease.
The US National Institute of Allergy and Infectious Diseases (NIAID), who cosponsored the trial said the results are “very good news” for the fight against Ebola.
The drugs REGN-EB3 and mAb114, attack the Ebola virus with antibodies which neutralise its impact on human cells.
NIAID director, Dr Anthony Fauci, said they are the “first drugs that in a scientifically sound study have clearly shown a significant diminution in mortality” for Ebola patients.
A sense that Ebola is incurable and a lack of trust in medical workers in DR Congo has held back treatment of the virus.
Dr Fauci hopes that patients will now feel “more comfortable about seeking care early”.
In the latest trial survival rate for patients with a low level of the virus in their blood was as high as 94% when given REGN-EB3 and 89% when on mAb114.
Mr Farrar continued: “We won’t ever get rid of Ebola but we should be able to stop these outbreaks from turning into major national and regional epidemics.”